ATE414556T1 - Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten - Google Patents

Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten

Info

Publication number
ATE414556T1
ATE414556T1 AT03714958T AT03714958T ATE414556T1 AT E414556 T1 ATE414556 T1 AT E414556T1 AT 03714958 T AT03714958 T AT 03714958T AT 03714958 T AT03714958 T AT 03714958T AT E414556 T1 ATE414556 T1 AT E414556T1
Authority
AT
Austria
Prior art keywords
inhibitors
treat
vascular disease
peripheral vascular
prevent peripheral
Prior art date
Application number
AT03714958T
Other languages
German (de)
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Application granted granted Critical
Publication of ATE414556T1 publication Critical patent/ATE414556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03714958T 2002-03-22 2003-03-13 Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten ATE414556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02100290 2002-03-22

Publications (1)

Publication Number Publication Date
ATE414556T1 true ATE414556T1 (de) 2008-12-15

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03714958T ATE414556T1 (de) 2002-03-22 2003-03-13 Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten

Country Status (27)

Country Link
US (2) US9592267B2 (pl)
EP (1) EP1487541B1 (pl)
JP (1) JP4885424B2 (pl)
KR (1) KR20050004809A (pl)
CN (1) CN100540058C (pl)
AR (1) AR039103A1 (pl)
AT (1) ATE414556T1 (pl)
AU (1) AU2003219162B2 (pl)
BR (1) BRPI0308663B8 (pl)
CA (1) CA2478855C (pl)
CY (1) CY1108748T1 (pl)
DE (1) DE60324777D1 (pl)
DK (1) DK1487541T3 (pl)
EA (1) EA008495B1 (pl)
ES (1) ES2314191T3 (pl)
HR (1) HRP20040758B1 (pl)
IL (2) IL164211A0 (pl)
ME (1) ME00548B (pl)
MX (1) MXPA04009135A (pl)
NO (1) NO336226B1 (pl)
PL (1) PL207303B1 (pl)
PT (1) PT1487541E (pl)
RS (1) RS51755B (pl)
SI (1) SI1487541T1 (pl)
UA (1) UA80275C2 (pl)
WO (1) WO2003080104A2 (pl)
ZA (1) ZA200407022B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
SK12942002A3 (sk) * 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
US9592267B2 (en) 2002-03-22 2017-03-14 Merck Serono Sa Use of IL-18BP for treatment of peripheral vascular diseases
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
JP2007532697A (ja) * 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 局所的血流増大の有益な効果
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
WO2009108890A1 (en) 2008-02-27 2009-09-03 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP2445493A1 (en) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topical composition containing naproxen
JP5844258B2 (ja) 2009-08-27 2016-01-13 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニーＢｉｏｍｅｔ Ｂｉｏｌｏｇｉｃｓ， Ｌｌｃ インターロイキン−１受容体アンタゴニストの生産のための植込み型装置
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
EP2658551B1 (en) 2010-12-29 2020-07-01 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
BR112022020256A2 (pt) 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
EP1101772B1 (en) * 1999-11-16 2009-01-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
CA2407895C (en) * 2000-05-05 2012-12-18 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US9592267B2 (en) 2002-03-22 2017-03-14 Merck Serono Sa Use of IL-18BP for treatment of peripheral vascular diseases

Also Published As

Publication number Publication date
NO20044459L (no) 2004-10-20
UA80275C2 (en) 2007-09-10
HK1075422A1 (zh) 2005-12-16
BRPI0308663B1 (pt) 2019-07-16
RS51755B (sr) 2011-12-31
HRP20040758A2 (en) 2005-02-28
ME00548B (me) 2011-10-10
US9592267B2 (en) 2017-03-14
EP1487541A2 (en) 2004-12-22
ZA200407022B (en) 2006-06-28
IL164211A (en) 2011-07-31
CN1655845A (zh) 2005-08-17
BRPI0308663B8 (pt) 2021-05-25
RS81504A (sr) 2006-12-15
WO2003080104A2 (en) 2003-10-02
US9566313B2 (en) 2017-02-14
CA2478855A1 (en) 2003-10-02
CN100540058C (zh) 2009-09-16
JP4885424B2 (ja) 2012-02-29
CA2478855C (en) 2013-12-17
AR039103A1 (es) 2005-02-09
EA008495B1 (ru) 2007-06-29
AU2003219162B2 (en) 2008-01-03
IL164211A0 (en) 2005-12-18
EP1487541B1 (en) 2008-11-19
AU2003219162A1 (en) 2003-10-08
SI1487541T1 (sl) 2009-02-28
MXPA04009135A (es) 2004-12-07
PL372398A1 (pl) 2005-07-25
HRP20040758B1 (hr) 2012-10-31
NO336226B1 (no) 2015-06-22
CY1108748T1 (el) 2014-04-09
WO2003080104A3 (en) 2004-03-04
US20060233799A1 (en) 2006-10-19
EA200401240A1 (ru) 2005-02-24
PL207303B1 (pl) 2010-11-30
PT1487541E (pt) 2008-12-10
DE60324777D1 (de) 2009-01-02
JP2005520852A (ja) 2005-07-14
KR20050004809A (ko) 2005-01-12
BR0308663A (pt) 2005-01-25
DK1487541T3 (da) 2009-01-19
ES2314191T3 (es) 2009-03-16
US20100291028A1 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
EP1622633A4 (en) Treatment of t-cell mediated diseases
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60327622D1 (de) Kombinierte antitachykardie - schrittmacher und hochspannungstherapie zur behandlung von ventrikulären arrhythmien
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
EP1742675A4 (en) TREATMENT OF BIOMEDICAL WASTE
ATE499105T1 (de) Behandlung oder vorbeugung von haut- oder gewebezuständen bei tieren unter verwendung von boryloxypyridylmethanonen
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
EP1191941A4 (en) METHOD OF PROPHYLAXIS AND / OR TREATMENT OF ILLNESSES
ATE509621T1 (de) Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE417616T1 (de) Behandlung von mukositis
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
EP1592464A4 (en) METHOD FOR THE TREATMENT OF COGNITIVE EXPOSURE TO SLEEP LEAVES AND STRESS
DE60314003D1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
ATE518531T1 (de) Alpha-humulene zur verwendung bei der prophylaxe oder behandlung der entzündlichen schmerzen und des ödems
ATE410169T1 (de) Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
EP1817039A4 (en) Treatment and prevention of epilepsy
ATE257384T1 (de) Verwendung von cilobradine oder pharmazeutisch akzeptablen salze zur behandlung oder prävention von herzversagen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487541

Country of ref document: EP

EEFA Change of the company name